Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Published species reactivity||Rat, Human|
|Host / Isotype||Mouse / IgG1, kappa|
|Immunogen||A synthetic peptide corresponding to aa625-643 of hNIS protein|
|Storage buffer||PBS, pH 7.4, with 0.2% BSA|
|Contains||15mM sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||1:400-800|
|Western Blot (WB)||Assay Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA5-12308 targets Sodium Iodide Symporter in IHC (P) and WB applications and shows reactivity with Human samples.
The MA5-12308 immunogen is a synthetic peptide corresponding to aa625-643 of hNIS protein.
Human Sodium Iodide Symporter (hNIS) is responsible for iodide concentrating ability within thyroid follicular cells. It is a membrane bound glycoprotein with 13 membrane spanning domains and 14 extramembranous domains. It may represent an autoantigen in thyroid. Antibody to NIS showed strong immunostaining in Graves¦ tissues, intermediate staining in papillary and follicular thyroid cancer, and no staining in Hurtle cell cancer or in nonthyroidal tissue.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Long-term effects of hepatocyte growth factor gene therapy in rat myocardial infarct model.
MA5-12308 was used in western blot to investigate the therapeutic effect of hepatocyte growth factor gene transfer in a rat myocardial infarct model
|Jin YN,Inubushi M,Masamoto K,Odaka K,Aoki I,Tsuji AB,Sagara M,Koizumi M,Saga T||Gene therapy (19:836)||2012|
Human sodium-iodide symporter (hNIS) gene expression is inhibited by a trans-active transcriptional repressor, NIS-repressor, containing PARP-1 in thyroid cancer cells.
MA5-12308 was used in western blot to investigate the mechanism of human sodium-iodide symporter regulation in thyroid cancer cells
|Li W,Ain KB||Endocrine-related cancer (17:383)||2010|
Immunoanalysis indicates that the sodium iodide symporter is not overexpressed in intracellular compartments in thyroid and breast cancers.
MA5-12308 was used in western blot to study sodium iodide symporter expression in thyroid and breast cancers
|Peyrottes I,Navarro V,Ondo-Mendez A,Marcellin D,Bellanger L,Marsault R,Lindenthal S,Ettore F,Darcourt J,Pourcher T||European journal of endocrinology / European Federation of Endocrine Societies (160:215)||2009|
Visualization of hypoxia-inducible factor-1 transcriptional activation in C6 glioma using luciferase and sodium iodide symporter genes.
MA5-12308 was used in western blot to examine the transcriptional activation of hypoxia-inducible factor-1 in C6 glioma
|Yeom CJ,Chung JK,Kang JH,Jeon YH,Kim KI,Jin YN,Lee YM,Jeong JM,Lee DS||Journal of nuclear medicine : official publication, Society of Nuclear Medicine (49:1489)||2008|
A novel loss-of-function deletion in sodium/iodide symporter gene in follicular thyroid adenoma.
MA5-12308 was used in western blot to study the sodium/iodide symporter gene mutation in follicular thyroid adenoma
|Liang JA,Chen CP,Huang SJ,Ho TY,Hsiang CY,Ding HJ,Wu SL||Cancer letters (230:65)||2005|
The pan-DAC inhibitor LBH589 is a multi-functional agent in breast cancer cells: cytotoxic drug and inducer of sodium-iodide symporter (NIS).
MA5-12308 was used in immunocytochemistry to investigate the effect of LBH589 on breast cancer cells and its mechanism
|Fortunati N,Catalano MG,Marano F,Mugoni V,Pugliese M,Bosco O,Mainini F,Boccuzzi G||Breast cancer research and treatment (124:667)||2010|
Targeting sodium/iodide symporter gene expression for estrogen-regulated imaging and therapy in breast cancer.
MA5-12308 was used in immunocytochemistry to study the use of adenovirus-expressed sodium iodide symporter for imaging and therapy of ER-positive breast tumors
|Montiel-Equihua CA,Martín-Duque P,de la Vieja A,Quintanilla M,Burnet J,Vassaux G,Lemoine NR||Cancer gene therapy (15:465)||2008|
Immunohistochemical expression of the human sodium/iodide symporter distinguishes malignant from benign gastric lesions.
MA5-12308 was used in immunohistochemistry to investigate the diagnostic value of sodium/iodide symporter expression in malignant and benign gastric lesions
|Farnedi A,Eusebi LH,Poli F,Foschini MP||International journal of surgical pathology (17:327)||2009|
Sodium iodide symporter is expressed at the preneoplastic stages of liver carcinogenesis and in human cholangiocarcinoma.
MA5-12308 was used in immunohistochemistry to study the role of the sodium iodide symporter in human cholangiocarcinoma
|Liu B,Hervé J,Bioulac-Sage P,Valogne Y,Roux J,Yilmaz F,Boisgard R,Guettier C,Calès P,Tavitian B,Samuel D,Clerc J,Bréchot C,Faivre J||Gastroenterology (132:1495)||2007|
Na(+)/I(-) cotransporter; Na(+)/I(-) symporter; Na(+)/I(-)-symporter; sodium/iodide cotransporter; solute carrier family 5 (sodium iodide symporter), member 5; solute carrier family 5 (sodium/iodide cotransporter), member 5; solute carrier family 5 member 5
NIS; SLC5A5; TDH1